Bank of America’s Sonnet BioTherapeutics SONN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-16,784
Closed -$76.9K 8247
2025
Q3
$76.9K Buy
16,784
+16,755
+57,776% +$74.3K ﹤0.01% 6700
2025
Q2
$36 Buy
29
+3
+12% +$4 ﹤0.01% 8164
2025
Q1
$35 Buy
26
+21
+420% +$32 ﹤0.01% 8040
2024
Q4
$7 Buy
+5
New +$17 ﹤0.01% 8107
2024
Q3
Sell
-4
Closed -$27 8389
2024
Q2
$27 Buy
4
+3
+300% +$40 ﹤0.01% 7949
2024
Q1
$11 Buy
+1
New +$13 ﹤0.01% 7541
2023
Q4
Sell
-12
Closed -$270 8208
2023
Q3
$270 Buy
+12
New +$630 ﹤0.01% 7378
2023
Q2
Hold
0
7663
2023
Q1
Hold
0
7733
2022
Q4
Hold
0
8163
2022
Q3
Hold
0
8171
2022
Q2
Hold
0
8352
2022
Q1
Hold
0
8716
2021
Q4
Hold
0
8604
2021
Q3
Hold
0
8372
2021
Q2
Hold
0
8063
2021
Q1
Hold
0
7747
2020
Q4
Hold
0
7348
2020
Q3
Hold
0
7149
2020
Q2
Hold
0
7107
2020
Q1
Hold
0
6649
2019
Q4
Hold
0
6844
2019
Q3
Hold
0
6900
2019
Q2
Hold
0
6822
2019
Q1
Hold
0
6685
2018
Q4
Hold
0
6709
2018
Q3
Hold
0
6600
2018
Q2
Hold
0
6569
2018
Q1
Hold
0
6379
2017
Q4
Hold
0
6591
2017
Q3
Hold
0
6514
2017
Q2
Hold
0
6358
2017
Q1
Hold
0
6419
2016
Q4
Hold
0
6381
2016
Q3
Hold
0
6056
2016
Q2
Hold
0
6294
2016
Q1
Hold
0
5136
2015
Q4
Hold
0
5236
2015
Q3
Sell
-1
Closed -$1.18M 5117
2015
Q2
$996K Buy
+1
New +$1.88M ﹤0.01% 4116
2015
Q1
Hold
0
5220
2014
Q4
Hold
0
6509
2014
Q3
Hold
0
6594
2014
Q2
Hold
0
6573
2014
Q1
Hold
0
6129
2013
Q4
Hold
0
6026
2013
Q3
Hold
0
5946
2013
Q2
Hold
0
6427

Other funds holding SONN

Bank of America's SONN Position: Q4 2025 in Review

Bank of America sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 16,784 shares — an estimated $76.9K sold.

Bank of America first reported a position in SONN in Q2 2015 and held it in 8 quarters. The position peaked at $996K in Q2 2015. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

  • Bank of America reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
  • Bank of America sold 16,784 Sonnet BioTherapeutics shares in Q4 2025, an estimated $76.9K.
  • Bank of America first reported a position in Sonnet BioTherapeutics in Q2 2015 and held it in 8 quarters.
  • Bank of America's Sonnet BioTherapeutics position peaked at $996K in Q2 2015.
  • 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Bank of America's 13F filing for Q4 2025, filed 17 Feb 2026.